scholarly journals Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer

2020 ◽  
Vol 29 (4) ◽  
pp. 662-673 ◽  
Author(s):  
Lucas A Salas ◽  
Sara N Lundgren ◽  
Eva P Browne ◽  
Elizabeth C Punska ◽  
Douglas L Anderton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Breast Milk ◽  
Cancer Diagnosis ◽  
Breast Biopsy ◽  
Disease Risk ◽  
Breast Cancer Diagnosis ◽  
Milk Samples ◽  
Cpg Sites ◽  
History Of

Abstract Prior candidate gene studies have shown tumor suppressor DNA methylation in breast milk related with history of breast biopsy, an established risk factor for breast cancer. To further establish the utility of breast milk as a tissue-specific biospecimen for investigations of breast carcinogenesis, we measured genome-wide DNA methylation in breast milk from women with and without a diagnosis of breast cancer in two independent cohorts. DNA methylation was assessed using Illumina HumanMethylation450k in 87 breast milk samples. Through an epigenome-wide association study we explored CpG sites associated with a breast cancer diagnosis in the prospectively collected milk samples from the breast that would develop cancer compared with women without a diagnosis of breast cancer using linear mixed effects models adjusted for history of breast biopsy, age, RefFreeCellMix cell estimates, time of delivery, array chip and subject as random effect. We identified 58 differentially methylated CpG sites associated with a subsequent breast cancer diagnosis (q-value <0.05). Nearly all CpG sites associated with a breast cancer diagnosis were hypomethylated in cases compared with controls and were enriched for CpG islands. In addition, inferred repeat element methylation was lower in breast milk DNA from cases compared to controls, and cases exhibited increased estimated epigenetic mitotic tick rate as well as DNA methylation age compared with controls. Breast milk has utility as a biospecimen for prospective assessment of disease risk, for understanding the underlying molecular basis of breast cancer risk factors and improving primary and secondary prevention of breast cancer.

scholarly journals Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer

2019 ◽  
Author(s):  
Lucas A Salas ◽  
Sara N. Lundgren ◽  
Eva P. Browne ◽  
Elizabeth C. Punska ◽  
Douglas L. Anderton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Breast Milk ◽  
Cancer Diagnosis ◽  
Breast Biopsy ◽  
Breast Cancer Diagnosis ◽  
Cell Type ◽  
Milk Samples ◽  
Cpg Sites ◽  
History Of

ABSTRACTBackgroundPrior candidate gene studies have shown tumor suppressor DNA methylation in breast milk related with history of breast biopsy, an established risk factor for breast cancer. To further establish the utility of breast milk as a tissue-specific biospecimen for investigations of breast carcinogenesis we measured genome-wide DNA methylation in breast milk from women with and without a diagnosis of breast cancer in two independent cohorts.MethodsDNA methylation was assessed using Illumina HumanMethylation450k in 87 breast milk samples. After quality control, 368,171 autosomal CpG loci were analyzed. Cell type proportion estimates from RefFreeCellMix were calculated and adjusted for in this Epigenome Wide Association Study using linear mixed effects models adjusted for history of breast biopsy, age, time of delivery, cell type proportion estimates, array chip, and subject as random effect.ResultsEpigenome-wide analyses identified 58 differentially methylated CpG sites associated with a breast cancer diagnosis in the prospectively collected milk samples from the breast that would develop cancer compared with women without a diagnosis of breast cancer (q-value < 0.05). Nearly all CpG sites associated with a breast cancer diagnosis were hypomethylated in cases compared with controls, and were enriched for CpG islands. In addition, inferred repeat element methylation was lower in breast milk DNA from cases compared to controls, and cases exhibited increased estimated epigenetic mitotic tick rate as well as DNA methylation age compared with controls.ConclusionBreast milk has utility as a biospecimen for prospective assessment of disease risk, for understanding the underlying molecular basis of breast cancer risk factors, and improving primary and secondary prevention of breast cancer.

A survival comparison between women with uterine serous and/or clear cell carcinoma with and without a history of breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5580-5580
Author(s):  
A. Mendivil ◽  
T. J. Vogel ◽  
V. L. Bae-Jump ◽  
P. A. Gehrig
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Cancer Diagnosis ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Uterine Cancer ◽  
Breast Cancer Diagnosis ◽  
Prior History ◽  
Type Ii ◽  
History Of

5580 Background: The association between breast and uterine is well known. However, the effect that a prior breast cancer diagnosis may have on women with a new endometrial cancer diagnosis is less well described. The goal of our study was to determine the effect that a prior history of breast cancer would have on the outcome for women with type II uterine cancer. Methods: After obtaining IRB exemption, a retrospective chart review was performed. All women treated for uterine carcinoma between 1994 and 2007 were identified and we identified women with either uterine serous (UPSC) or clear cell carcinoma (UCCC) as the study group. The patients were then divided between those with and those without a prior breast cancer diagnosis. Patient demographics, cancer histologies, and stage of disease data were collected. Fisher's exact test and unpaired t test were used as appropriate. Progression-free (PFS) and overall survival (OS) were calculated using the Kaplan Meier method. Results: Approximately 1,083 patients were treated for uterine carcinoma during the study period of which 74 had pre-existing breast carcinoma (6.9%). One hundred and fifty women had USC and/or UCCC (13.8%) of whom 23 also had pre-existing breast carcinoma (13.3%). The women with breast cancer where older at the time of their uterine cancer diagnosis (77 y.o.) compared to those without breast cancer (68 y.o.) (p = 0.0089); were more likely to develop USC/UCCC (OR 2.56; 95% CI 1.47–4.44); and were more likely to be white compared to black (OR 4.6; 95% CI 1.74–11.99). At five years, there was no significant difference in PFS or OS between those women with and without a prior history of breast cancer. Conclusions: Women with a history of breast cancer have more the twice the likelihood of developing USC and/or UCCC. While having two primary malignancies can be devastating, our study indicated that women who developed a type II uterine cancer and also had a history of a prior breast cancer had the same outcomes as those women without a prior cancer diagnosis. This finding may help to allay patients’ fears about developing another malignancy and its impact on their prognosis. No significant financial relationships to disclose.

scholarly journals Reproductive Factors and Breast Cancer Prognosis: The Possible Role of Cesarean Delivery

Acta Medica ◽  
2021 ◽  
pp. 1-8
Author(s):  
Seda Hanife Oguz ◽  
Güngör Utkan
Keyword(s):  
Breast Cancer ◽  
Cesarean Delivery ◽  
Cancer Diagnosis ◽  
Reproductive Factors ◽  
Breast Cancer Diagnosis ◽  
Time Interval ◽  
Axillary Lymph ◽  
Term Pregnancy ◽  
History Of ◽  
Extracapsular Invasion

Objective: To evaluate the possible associations between tumor pathological characteristics and reproductive factors in women with breast cancer, including method of child delivery. Materials and Methods: Patients diagnosed as breast cancer between January 2012 and April 2013 in Ankara University Hospitals who had at least one full term pregnancy were included. Data upon pathological prognostic features of tumors and reproductive history of patients were obtained from patient files. Results: 434 patients with breast cancer were included. Mean age at the time of breast cancer diagnosis was 49.2±10.7 years. History of at least one cesarean delivery was present in 17% of the patients (n=75). Axillary lymph node positivity was related to younger age at first full-term pregnancy (p=0.018), and higher number of parities (p=0.001) in estrogen receptor positive (ER+) breast cancer patients. Although extracapsular invasion was related to shorter time interval since last parity to cancer diagnosis in the whole population (p=0.029), this association disappeared when patients were categorized according to ER status. However, in ER+ patients, history of cesarean delivery was associated with extracapsular invasion (p=0.023). Also, our findings indicated that patients with history of cesarean delivery were diagnosed with breast cancer at younger ages, and after a shorter time interval since last parity (p<0.001). Tumor size (p=0.001), grade (p=0.046), axillary lymph node positivity (p=0.001), lymphovascular invasion (p<0.001), and shorter duration of time since last parity to breast cancer diagnosis (p=0.029) were indicators of metastatic disease. Conclusion: Our findings indicate that history of cesarean delivery may be associated with poor prognosis in ER+ patients with breast cancer.

scholarly journals A Case of Breastfeeding With Active Breast Cancer

2019 ◽  
Vol 10 (3) ◽  
pp. 136-140 ◽  
Author(s):  
Erika Gergerich ◽  
Bethany Garling-Spychala
Keyword(s):  
Breast Cancer ◽  
Breast Milk ◽  
Cancer Treatment ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Donor Milk ◽  
Geographic Barriers ◽  
Different Types ◽  
Active Cancer

IntroductionPregnancy-associated breast cancer is relatively uncommon, with few guidelines for management. Women with an active breast cancer diagnosis who wish to offer their children breast milk (either first or second hand) face a number of obstacles and gaps in information.MethodThis article presents a case study and summary of current research on the topic of breastfeeding and breast cancer.Results and DiscussionDifferent types of cancer and cancer treatment influence whether a woman will be able to breastfeed. Some mothers can resume breastfeeding after treatment. If treatment is lengthy, breastfeeding may need to cease permanently. Mothers may need to take medications to help them wean. Finally some mothers may use donor milk to feed their babies once they are no longer able to breastfeed.ConclusionsFurther research is needed to determine and formalize guidelines related to the safety of breastfeeding with an active cancer diagnosis. And there is a need for increased access to breast milk for mothers who are unable to breastfeed. There are geographic barriers, as well as obstacles related to availability and cost.

Risk of colon adenoma in patients with breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1541-1541
Author(s):  
Yinghong Wang ◽  
Hamzah Abu-Sbeih ◽  
Faisal Ali ◽  
Phillip S. Ge ◽  
Carlos Hernando Barcenas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Logistic Regression ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Screening Colonoscopy ◽  
Multivariate Logistic Regression ◽  
Colon Adenoma ◽  
Adenoma Detection ◽  
Increased Risk ◽  
History Of

1541 Background: In our clinical practice at a tertiary cancer center, we have observed increased adenoma detection rate (ADR) in patients with breast cancer. Here, we describe ADR in patients with breast cancer to define the appropriate timing to initiate colonoscopy screening in these patients. Methods: We conducted a retrospective study of patients with breast cancer who underwent a colonoscopy after their diagnosis of breast cancer between 2000 and 2017. A control group ( n = 3295) comprised patients without any type of cancer who underwent their first screening colonoscopy between 2008 and 2017 was used in the logistic regression. Results: Of the 62,820 patients who had a diagnosis of breast cancer, 3304 were included. The mean age was 59 years. Regarding ADR, 1803 patients (55%) had adenomas. High-grade dysplasia was evident in 28% of polyps and invasive adenocarcinoma in 172 (5%). The median time from breast cancer diagnosis to adenoma detection was 3 years (IQR 1-6). The ADR was 21% in patients younger than 40 years ( n=63), 39% in patients between 40 and 50 years ( n=314), 54% in patients between 50 and 60 years ( n=1420), and 60% in patients older than 60 years ( n=1507). ADR in patients younger than 50 years of age who do not have a family history of colorectal cancer or a body mass index (BMI) higher than 30 kg/m2 was 26%. A subsequent colonoscopy was performed in 831 patients who had colonic adenoma in the initial colonoscopy. The ADR was 40% in patients who had a repeat colonoscopy within 3 years, 50% within 3-5 years, and 53% > 5 years. Multivariate logistic regression analyses revealed an increased risk of colon adenoma with older age, male sex, higher BMI, and personal history of breast cancer ( P<0.05). Conclusions: In patients with breast cancer, ADR was higher than that of patients without history of cancer. Notably, breast cancer was an independent risk factor for colon adenoma. In patients who are younger than 40 years of age, screening colonoscopy should be considered within five years of breast cancer diagnosis. Multivariate logistic regression: risk factors of adenoma. [Table: see text]

scholarly journals Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study

2011 ◽  
Vol 29 (18) ◽  
pp. 2466-2473 ◽  
Author(s):  
Elena B. Elkin ◽  
Michelle L. Klem ◽  
Anne Marie Gonzales ◽  
Nicole M. Ishill ◽  
David Hodgson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Hodgkin’S Lymphoma ◽  
Sporadic Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Hodgkin's Lymphoma ◽  
Increased Risk ◽  
History Of ◽  
Cancer Specific Mortality

Purpose To compare characteristics and outcomes of breast cancer in women with and without a history of radiation therapy (RT) for Hodgkin's lymphoma (HL). Patients and Methods Women with breast cancer diagnosed from 1980 to 2006 after RT for HL were identified from eight North American hospitals and were matched three-to-one with patients with sporadic breast cancer by age, race, and year of breast cancer diagnosis. Information on patient, tumor and treatment characteristics, and clinical outcomes was abstracted from medical records. Results A total of 253 patients with breast cancer with a history of RT for HL were matched with 741 patients with sporadic breast cancer. Median time from HL to breast cancer diagnosis was 18 years. Median age at breast cancer diagnosis was 42 years. Breast cancer after RT for HL was more likely to be detected by screening, was more likely to be diagnosed at an earlier stage, and was more likely to be bilateral at diagnosis. HL survivors had an increased risk of metachronous contralateral breast cancer (adjusted hazard ratio [HR], 4.3; 95% CI, 1.7 to 11.0) and death as a result of any cause (adjusted HR, 1.9; 95% CI, 1.1 to 3.3). Breast cancer–specific mortality was also elevated, but this difference was not statistically significant (adjusted HR, 1.6; 95% CI, 0.7 to 3.4). Conclusion In women with a history of RT for HL, breast cancer is diagnosed at an earlier stage, but these women are at greater risk for bilateral disease and are more likely to die as a result of causes other than breast cancer. Our findings support close follow-up for contralateral tumors in these patients and ongoing primary care to manage comorbid conditions.

Sign in / Sign up

Export Citation Format

Share Document